Loading...
OTCM
CVSI
Market cap4mUSD
Jul 09, Last price  
0.02USD
1D
4.76%
1Q
-39.04%
Jan 2017
-94.88%
IPO
-99.56%
Name

CV Sciences Inc

Chart & Performance

D1W1MN
OTCM:CVSI chart
P/E
P/S
0.33
EPS
Div Yield, %
Shrs. gr., 5y
13.02%
Rev. gr., 5y
-10.81%
Revenues
14m
-12.20%
002,154,06310,190,66711,529,40211,060,63620,679,23948,244,00053,696,00024,429,00020,048,00016,205,00016,004,00015,705,00013,789,000
Net income
-958k
L-59.98%
-90,180-45,611-2,300,196-1,311,951-12,233,128-14,141,298-4,897,13910,001,000-16,610,000-22,284,000-15,554,000-8,214,0003,102,000-2,394,000-958,000
CFO
-407k
L-52.73%
-79,632-64,084-4,879,234-6,712,000-4,208,267-2,053,7403,615,00412,559,000-2,138,000-7,300,000-7,485,000-1,885,0002,253,000-861,000-407,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.
IPO date
Oct 04, 2018
Employees
42
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT